Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

NCT02069886 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Thalassemia (Transfusion Delendent)

Interventions

DRUG: deferasirox

Sponsor

Novartis Pharmaceuticals